SpringWorks Therapeutics has been granted a patent for improved methods of treating desmoid tumors using nirogacestat. The method involves administering specific oral dosages of nirogacestat to patients, with careful monitoring and adjustments based on liver enzyme levels. GlobalData’s report on SpringWorks Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights SpringWorks Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on SpringWorks Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. SpringWorks Therapeutics's grant share as of February 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of desmoid tumor with nirogacestat in specific dosages

Source: United States Patent and Trademark Office (USPTO). Credit: SpringWorks Therapeutics Inc

A recently granted patent (Publication Number: US11925619B2) outlines a method for the therapeutic treatment of desmoid tumors in patients using nirogacestat or its pharmaceutically acceptable salt. The method involves administering an oral dosage of 150 mg of nirogacestat twice daily, with specific guidelines for adjusting the dosage based on liver enzyme levels. If the patient experiences elevated levels of alanine transaminase (ALT) or aspartate aminotransferase (AST), treatment should be temporarily withheld until levels return to normal, followed by a reduced dosage of 100 mg twice daily to resume treatment.

Furthermore, the patent claims that the administration of nirogacestat can lead to a reduction in the risk of disease progression, improvement in progression-free survival, and enhancements in objective response rate and quality of life assessments. The method also specifies that if the patient's ALT or AST levels exceed 5 times the upper limit of normal, treatment with nirogacestat should be permanently discontinued. Overall, this patent provides a detailed protocol for the effective and safe use of nirogacestat in the treatment of desmoid tumors, emphasizing the importance of monitoring liver enzyme levels to ensure patient safety and treatment efficacy.

To know more about GlobalData’s detailed insights on SpringWorks Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies